Use of multiple peptides containing T cell epitopes is a feasible approach for peptide-based immunotherapy in Can f 1 allergy.
We have previously shown that the major dog allergen Can f 1 contains seven T cell epitope regions, none of which was preferentially recognized. To identify the immune characteristics of Can f 1 epitopes and to verify their suitability for peptide-based allergen immunotherapy, short-term T cell lines were generated with epitope-containing peptides from peripheral blood mononuclear cells of Can f 1 skinprick test-positive allergic and healthy control subjects. The lines were examined for their proliferative capacity and cytokine production upon stimulation with the allergen peptide, a homologous peptide from human tear lipocalin (TL) and Can f 1 and TL proteins. Can f 1 peptides induced proliferation of T cells and gave rise to T cell lines with comparable efficiencies. In particular, the T cell lines of allergic subjects induced with p33-48 and p107-122 favoured the production of interferon-gamma and interleukin-10, respectively. A greater number of Can f 1-specific T cell lines were generated from allergic than from healthy individuals. Two p107-122-induced Can f 1-specific T cell lines also reacted to a homologous peptide of human TL. Our results suggest that several T cell epitope-containing peptides should be used in combination for specific immunotherapy in Can f 1 allergy.
Immonen
Anu K
AK
Department of Clinical Microbiology, University of Kuopio, Kuopio, Finland. Anu.Immonen@uku.fi
Taivainen
Antti H
AH
Närvänen
Ale T O
AT
Kinnunen
Tuure T
TT
Saarelainen
Soili A
SA
Rytkönen-Nissinen
Marja A
MA
Virtanen
Tuomas I
TI
D000485:Allergens / Q000276:immunology*; D000818:Animals; D052179:Antigens, Plant; D002460:Cell Line; D049109:Cell Proliferation; D002478:Cells, Cultured; D016207:Cytokines / Q000096:biosynthesis; D004285:Dogs; D004306:Dose-Response Relationship, Immunologic; D018984:Epitopes, T-Lymphocyte / Q000276:immunology*; D005240:Feasibility Studies; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology* / Q000628:therapy; D016130:Immunophenotyping; D007167:Immunotherapy / Q000379:methods; D007371:Interferon-gamma / Q000096:biosynthesis; D016753:Interleukin-10 / Q000096:biosynthesis; D015847:Interleukin-4 / Q000096:biosynthesis; D008213:Lymphocyte Activation / Q000276:immunology; D010446:Peptide Fragments / Q000276:immunology / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology
D000485:Allergens; D052179:Antigens, Plant; D016207:Cytokines; D018984:Epitopes, T-Lymphocyte; D010446:Peptide Fragments; C091462:allergen Can f I; D016753:Interleukin-10; D015847:Interleukin-4; D007371:Interferon-gamma